WesBanco, Inc. (WSBC)
NASDAQ: WSBC · Real-Time Price · USD
29.53
+0.09 (0.31%)
At close: Aug 8, 2025, 4:00 PM
29.52
-0.01 (-0.03%)
After-hours: Aug 8, 2025, 4:10 PM EDT
CTI BioPharma Stock Forecast
Stock Price Forecast
The 6 analysts that cover CTI BioPharma stock have a consensus rating of "Buy" and an average price target of $38.5, which forecasts a 30.38% increase in the stock price over the next year. The lowest target is $34 and the highest is $45.
Price Target: $38.5 (+30.38%)
Analyst Consensus: Buy
* Price targets were last updated on May 5, 2025.
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Keefe, Bruyette & Woods | Keefe, Bruyette & Woods | Buy Maintains $43 → $40 | Buy | Maintains | $43 → $40 | +35.46% | May 5, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $36 → $34 | Hold | Maintains | $36 → $34 | +15.14% | May 1, 2025 |
| Raymond James | Raymond James | Strong Buy Maintains $44 → $38 | Strong Buy | Maintains | $44 → $38 | +28.68% | Apr 2, 2025 |
| Keefe, Bruyette & Woods | Keefe, Bruyette & Woods | Hold → Buy Upgrades $40 → $44 | Hold → Buy | Upgrades | $40 → $44 | +49.00% | Feb 10, 2025 |
| DA Davidson | DA Davidson | Strong Buy Maintains $44 → $45 | Strong Buy | Maintains | $44 → $45 | +52.39% | Jan 27, 2025 |
Financial Forecast
Revenue This Year
836.02M
from 586.99M
Increased by 42.43%
Revenue Next Year
939.99M
from 836.02M
Increased by 12.44%
EPS This Year
3.44
from 2.26
Increased by 52.17%
EPS Next Year
3.94
from 3.44
Increased by 14.58%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 |
|---|---|---|
| High | 867.8M | 983.4M |
| Avg | 836.0M | 940.0M |
| Low | 795.4M | 890.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 |
|---|---|---|
| High | 47.8% | 17.6% |
| Avg | 42.4% | 12.4% |
| Low | 35.5% | 6.5% |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | 3.65 | 4.20 |
| Avg | 3.44 | 3.94 |
| Low | 3.23 | 3.68 |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | 61.8% | 22.2% |
| Avg | 52.2% | 14.6% |
| Low | 43.2% | 6.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.